Wednesday's session: top gainers and losers

BIOGEN INC (BIIB)       283.63   -3.89 (-1.35%)

After market: 283.5 -0.13 (-0.05%)


News Image
Wednesday's session: top gainers and losers4 months ago - Chartmill

Let's have a look at what is happening on the US markets one hour before the close of the markets on Wednesday. Below you can find the top gainers and losers in today's session.

Today's top gainers

TickerChangeComment
PRTA75.4%PROTHENA CORP PLC's (NASDAQ:PRTA) shares rose 75.4% to $54.25. In the last 6 months the stock lost 20.81%.
SOBR62.96%SOBR SAFE INC (NASDAQ:SOBR) rose 62.96% to $2.2 during Wednesday's after hours session. The stock is trading 27.96% higher than a month ago.
BTRS60.4%BTRS HOLDINGS INC-CL 1's (NASDAQ:BTRS) stock price increased by 60.4% to $9.26. Earlier today the company had a press release: BTRS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of BTRS Holdings Inc. Is Fair to Shareholders.
FNGR57.55%FINGERMOTION INC's (NASDAQ:FNGR) stock price is advancing with 57.55% to a price of $1.67. The stock is trading 21.54% lower than 3 months ago.
BIIB39.02%BIOGEN INC's (NASDAQ:BIIB) shares rose 39.02% to $274.97. In the last year the stock lost 30.34%.
BEAT33.43%HEARTBEAM INC's (NASDAQ:BEAT) shares rose 33.43% to $3.59 during Wednesday's session. Earlier today the company had a press release: HeartBeam Granted Patent for Signal Transformation from Vector Electrocardiogram (VECG) to 12-Lead Electrocardiogram (ECG).
QTRX32.36%QUANTERIX CORP's (NASDAQ:QTRX) shares rose 32.36% to $10.67 during Wednesday's session. The stock is trading 52.0% lower than 3 months ago.
KLXE28.79%KLX ENERGY SERVICES HOLDING's (NASDAQ:KLXE) stock price is advancing with 28.79% to a price of $6.89. The stock is trading 35.15% lower than a month ago.
STIM24.37%NEURONETICS INC's (NASDAQ:STIM) shares rose 24.37% to $2.96 during Wednesday's session. The stock is trading 38.66% lower than a month ago.
TOPS24.37%TOP SHIPS INC (NASDAQ:TOPS) rose 24.37% to $2.91 during Wednesday's after hours session. Shareholders saw the stock price going 59.84% lower in the past month.

To see the full list of top gainers you can use our top gainers screener.

Top losers

TickerChangeComment
PHAS-65.01%PHASEBIO PHARMACEUTICALS INC's (NASDAQ:PHAS) stock price is declining with 65.01% to a price of $0.27. In the last month the share price dropped with 32.74%.
MNMD-50.41%MIND MEDICINE MINDMED INC's (NASDAQ:MNMD) stock price is declining with 50.41% to a price of $3.04. In the last month the stock lost 49.04%.
IBIO-35.41%IBIO INC's (NYSEARCA:IBIO) stock price decreased by 35.41% to $0.2. In the last 3 months the stock gained 21.54%.
NA-33.02%NANO LABS LTD-ADR's (NASDAQ:NA) stock price decreased by 33.02% to $2.13. A press release (Nano Labs Ltd Announces Pricing of Public Offering of American Depositary Shares) was released yesterday.
HLBZW-31.14%HELBIZ INC-CW24's (NASDAQ:HLBZW) shares fell 31.14% to $0.07 during Wednesday's session. In the last 6 months the share price dropped with 65.67%.
GROV-25.71%GROVE COLLABORATIVE HOLDINGS's (NYSE:GROV) stock price is declining with 25.71% to a price of $2.98. Yesterday the company had a press release: Grove Co. Continues Retail Expansion with Entry Into Thousands of More Stores.
SONX-22.75%SONENDO INC's (NYSE:SONX) stock price is declining with 22.75% to a price of $1.29. In the last month the share price increased with 41.53%.
ALLG-22.62%ALLEGO NV's (NYSE:ALLG) stock price is declining with 22.62% to a price of $4.55. The stock is trading 51.55% higher than a month ago.
REVBW-21.82%REVELATION BIOSC -CW27's (NASDAQ:REVBW) shares fell 21.82% to $0.04. In the last month the stock lost 38.43%.
LYLT-21.71%LOYALTY VENTURES INC's (NASDAQ:LYLT) shares fell 21.71% to $1.37 during Wednesday's session. The stock is trading 21.88% lower than a month ago.

For the full top loser list go to our top losers screener.

Back

BIIB Links

BIIB News

News Imagea day ago - Investor's Business DailyHere's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric

The company that remains still has a large pipeline of non-migraine assets.

News Imagea day ago - Market News VideoMarch 24th Options Now Available For Biogen (BIIB)News Image2 days ago - InvestorPlaceThe 7 Most Undervalued Nasdaq Stocks to Buy in February 2023

For those seeking the best discounts in the tech-centered index, these are the most undervalued Nasdaq stocks to buy.

News Image3 days ago - Seeking AlphaIMUX stock climbs as Wedbush initiates with bullish view on lead asset (NASDAQ:IMUX)

Immunic (IMUX) climbed ~14% after Wedbush launched its coverage citing “best-in-class potential” for the company’s lead asset IMU-838 targeted multiple sclerosis. Read the full story here.

News Image4 days ago - InvestorPlace7 CRISPR Stocks With the Best Long-Term Potential

CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve.

News Image5 days ago - MarketBeatCassava Sciences Stock Undervalued with Its $124 Price Target?

Casava Sciences Inc (NASDAQ: SAVA) stock has been the topic of much controversy in its quest for FDA approval for its simufilam drug. The Company is a

News Image5 days ago - Biogen Inc.Lecanemab Receives Priority Review Status in JapanNews Image5 days ago - Biogen Inc.Lecanemab Receives Priority Review Status in Japan

TOKYO and CAMBRIDGE, Mass., Jan. 29, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq:...

News Image5 days ago - Eisai Inc.LECANEMAB RECEIVES PRIORITY REVIEW STATUS IN JAPAN

/PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,...

News Image8 days ago - Seeking AlphaJ&J pulls Imbruvica combo filing in EU as EMA cites potential 'serious side effects'

A committee of the European Medicines Agency ((EMA)) said that Johnson & Johnson (JNJ) withdrew its application seeking expanded approval of blood cancer drug Imbruvica on Dec

News Image8 days ago - Biogen Inc.Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines AgencyNews Image8 days ago - Biogen Inc.Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency

TOKYO and CAMBRIDGE, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq:...

Follow us for more